Wittkop, Linda ORCID: 0000-0003-2403-0960, Arsandaux, Julie ORCID: 0000-0002-3036-5866, Trevino, Ana, van der Loeff, Maarten Schim, Anderson, Jane ORCID: 0000-0001-5294-8707, van Sighem, Ard, Boni, Jurg, Brun-Vezinet, Francoise, Soriano, Vicente ORCID: 0000-0002-4624-5199, Boufassa, Faroudy, Brockmeyer, Norbert, Calmy, Alexandra, Dabis, Francois, Jarrin, Inma, Dorrucci, Maria, Duque, Vitor ORCID: 0000-0003-0000-4004, Faetkenheuer, Gerd, Zangerle, Robert, Ferrer, Elena, Porter, Kholoud ORCID: 0000-0002-9226-6206, Judd, Ali, Sipsas, Nikolaos V., Lambotte, Olivier, Shepherd, Leah, Leport, Catherine, Morrison, Charles, Mussini, Cristina, Obel, Niels, Ruelle, Jean, Schwarze-Zander, Carolyne, Sonnerborg, Anders ORCID: 0000-0001-8928-3374, Teira, Ramon, Torti, Carlo, Valadas, Emilia ORCID: 0000-0001-5213-1473, Colin, Celine, Friis-Moller, Nina, Costagliola, Dominique ORCID: 0000-0003-0765-0869, Thiebaut, Rodolphe, Chene, Genevieve and Matheron, Sophie (2017). CD4 cell count response to first-line combination ART in HIV-2+patients compared with HIV-1+patients: a multinational, multicohort European study. J. Antimicrob. Chemother., 72 (10). S. 2869 - 2879. OXFORD: OXFORD UNIV PRESS. ISSN 1460-2091

Full text not available from this repository.

Abstract

Background: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL). Methods: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models. Results: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36-52) and 37 years (IQR 31-44), respectively. Median observed pretreatment CD4 cell counts/mm(3) were 203 (95% CI 100-290) in HIV-2+ patients and 223 (95% CI 100-353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12months were + 105 (95% CI 77-134) in HIV-2+ patients and + 202 (95% CI 199-205) in HIV-1+ patients, an observed difference of 97 cells/mm(3) in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm(3)/year lower (95% CI 5-44; P=0.0127) in HIV-2+ patients compared with HIV-1+ patients. Conclusions: A poorer CD4 cell increase during first-line cART was observed in HIV-2+ patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Wittkop, LindaUNSPECIFIEDorcid.org/0000-0003-2403-0960UNSPECIFIED
Arsandaux, JulieUNSPECIFIEDorcid.org/0000-0002-3036-5866UNSPECIFIED
Trevino, AnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
van der Loeff, Maarten SchimUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Anderson, JaneUNSPECIFIEDorcid.org/0000-0001-5294-8707UNSPECIFIED
van Sighem, ArdUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boni, JurgUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brun-Vezinet, FrancoiseUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Soriano, VicenteUNSPECIFIEDorcid.org/0000-0002-4624-5199UNSPECIFIED
Boufassa, FaroudyUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brockmeyer, NorbertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Calmy, AlexandraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dabis, FrancoisUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jarrin, InmaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dorrucci, MariaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Duque, VitorUNSPECIFIEDorcid.org/0000-0003-0000-4004UNSPECIFIED
Faetkenheuer, GerdUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zangerle, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ferrer, ElenaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Porter, KholoudUNSPECIFIEDorcid.org/0000-0002-9226-6206UNSPECIFIED
Judd, AliUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sipsas, Nikolaos V.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lambotte, OlivierUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Shepherd, LeahUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Leport, CatherineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Morrison, CharlesUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mussini, CristinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Obel, NielsUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ruelle, JeanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schwarze-Zander, CarolyneUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sonnerborg, AndersUNSPECIFIEDorcid.org/0000-0001-8928-3374UNSPECIFIED
Teira, RamonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Torti, CarloUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Valadas, EmiliaUNSPECIFIEDorcid.org/0000-0001-5213-1473UNSPECIFIED
Colin, CelineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Friis-Moller, NinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Costagliola, DominiqueUNSPECIFIEDorcid.org/0000-0003-0765-0869UNSPECIFIED
Thiebaut, RodolpheUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chene, GenevieveUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Matheron, SophieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-216713
DOI: 10.1093/jac/dkx210
Journal or Publication Title: J. Antimicrob. Chemother.
Volume: 72
Number: 10
Page Range: S. 2869 - 2879
Date: 2017
Publisher: OXFORD UNIV PRESS
Place of Publication: OXFORD
ISSN: 1460-2091
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
NAIVE HIV-2-INFECTED PATIENTS; VIRUS TYPE-2 HIV-2; PLASMA VIRAL LOAD; WEST-AFRICA; INTERNATIONAL COLLABORATION; PHENOTYPIC SUSCEPTIBILITY; ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; PROTEASE INHIBITORS; IMMUNE ACTIVATIONMultiple languages
Infectious Diseases; Microbiology; Pharmacology & PharmacyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/21671

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item